Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OSR Holdings, Inc. (OSRH)
USD0.42
+0.06 (+16.10%)
US NASDAQ Healthcare Biotechnology
Address
10900 NE 4th Street 98004
Bellevue, WA, US
Bellevue, WA, US
CEO
Kuk Hyoun Hwang
Website
osr-holdings.com
IPO
2023-03-21
CIK 1840425 ISIN US68840D1028
Also trades on
NASDAQ Capital Market · BLAC (USD)
NASDAQ Capital Market · BLACU (USD)
NASDAQ Global Market · OSRH (USD)
NASDAQ Global Market · OSRHW (USD)
Description
OSR Holdings, Inc. operates as a Special Purpose Acquisition Company (SPAC) – essentially a blank check entity. Its primary objective is to execute a substantial business combination, which may take the form of a merger, a capital stock exchange, an asset acquisition, a stock purchase, a reorganization, or other comparable strategic transaction with one or more established businesses. The company was incorporated on February 25, 2020, and maintains its principal office in Bellevue, Washington.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.42
+0.06 (+16.10%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.61
Float Shares
7.66M
Free Float %
30.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.02% | -3.23% | +0.00% | +24.02% | +17.48% | +1.05% | -49.56% | -94.40% | -94.36% | -94.36% | -94.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.42
DCF (Unlevered)
6.24
+1,383.6%
DCF (Levered)
1.33
+217.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-0.62
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-17.7% Q1'26: -36.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-644.4% Q1'26: +69.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-558.3% Q1'26: -207.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-976.7% Q1'26: -757.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-21.9% Q1'26: -9.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.23× Q1'26: -1.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|
| Revenue |
2.91M
est: 3.42M (-15.0%)
|
3.11M
3.11M – 3.11M
-8.9% YoY
|
71.65M
71.65M – 71.65M
+2,200.9% YoY
|
| EBITDA |
-19.08M
est: 951.2K (-2,105.4%)
|
866.3K
866.3K – 866.3K
-8.9% YoY
|
19.93M
19.93M – 19.93M
+2,200.9% YoY
|
| EBIT |
-28.38M
est: 683.9K (-4,250.3%)
|
622.8K
622.8K – 622.8K
-8.9% YoY
|
14.33M
14.33M – 14.33M
+2,200.9% YoY
|
| Net Income |
-18.01M
est: -4.35M (-314.3%)
|
-4.89M
-4.89M – -4.89M
-12.4% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
9.19M
est: 4.71M (+95.3%)
|
4.29M
4.29M – 4.29M
-8.9% YoY
|
98.61M
98.61M – 98.61M
+2,200.9% YoY
|
| EPS |
-4.02
est: -0.97 (-314.4%)
|
-1.09
-1.09 – -1.09
-12.4% YoY
|
—
— – —
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.33M
OE per share TTM
-1.19
Owner's Yield
-208.67%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bellevue Capital Management LLC | 2.04M | 36.20% | 2.04M | — | 2.04M | — | OO | — | 2024-02-08 | ↗ |
| 2 | Bellevue Global Life Science Investors, LLC | 2.04M | 36.20% | 2.04M | — | 2.04M | — | OO | — | 2024-02-08 | ↗ |
| 3 | Kuk Hyoun Hwang | 2.04M | 36.20% | 2.04M | — | 2.04M | — | IN | — | 2024-02-08 | ↗ |
| 4 | Space Summit Capital LLC | 400.0K | 6.67% | 400.0K | — | 400.0K | — | — | Delaware | 2023-02-16 | ↗ |
| 5 | RIVERNORTH CAPITAL MANAGEMENT, LLC | 245.1K | 6.07% | 245.1K | — | 245.1K | — | IA | DELAWARE | 2024-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 15.9K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.56
Neutral
Ratio by volume
2.67
Bullish
Buys
15
Sells
27
Shares acquired
2.35M
Shares disposed
879.0K
Cash buys
2.00
Cash sales
—
Net activity
+1,471,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-26 | Kim Yeiseok | Officer | — | — | Common Stock | 0 | 0.00 | — | 24,699 | D | ↗ |
| 2025-09-17 | Fierz Reto Kaspar | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-14 | Kim Sang Harry | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-14 | Jee Hyuk Joo | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-14 | Hwang Kuk Hyoun | Director / Officer / 10% Owner | J-Other | A | Common Stock | 3,123,970 | 0.00 | — | 12,699,104 | I | ↗ |
| 2025-02-14 | Cho Joong Myung | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-14 | Bellevue Global Life Science Investors LLC | 10% Owner | J-Other | A | Common Stock | 43,000 | 0.00 | — | 2,043,500 | D | ↗ |
| 2025-02-14 | Bellevue Capital Management LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 3,123,970 | D | ↗ |
| 2025-02-14 | Barberis Alcide | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-14 | Bang Gihyoun | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-14 | BCM Europe AG | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 7,531,634 | D | ↗ |
| 2024-06-23 | Kim Sang Hyun | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-05-27 | Lee Phil Geon | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-03-23 | Yoo David Jin | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-03-23 | Hwang Kuk Hyoun | Director / Officer / 10% Owner | J-Other | D | Common Stock | 20,000 | 0.00 | — | 2,000,500 | — | ↗ |
| 2023-03-23 | Bellevue Global Life Science Investors LLC | 10% Owner | J-Other | D | Common Stock | 20,000 | 0.00 | — | 2,000,500 | — | ↗ |
| 2023-02-21 | Hwang Kuk Hyoun | Director / Officer / 10% Owner | J-Other | A | Common Stock | 225,000 | 0.00 | — | 2,025,000 | — | ↗ |
| 2023-02-21 | Bellevue Global Life Science Investors LLC | 10% Owner | J-Other | A | Common Stock | 225,000 | 0.00 | — | 2,025,000 | — | ↗ |
| 2023-02-14 | Roberts Rad | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-02-14 | REED STEVEN | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-02-14 | Park Jin Whan | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-02-14 | Hwang Kuk Hyoun | Director / Officer / 10% Owner | J-Other | D | Common Stock | 20,000 | 0.00 | — | 1,665,000 | — | ↗ |
| 2023-02-14 | Euh Hosun | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-02-14 | Chung In Chul | Director | A-Award | A | Warrant for Common Stock | 20,000 | 11.50 | 230.0K | 20,000 | — | ↗ |
| 2023-02-14 | Bellevue Global Life Science Investors LLC | 10% Owner | A-Award | A | Common Stock | 430,000 | 10.00 | 4.30M | 1,800,000 | — | ↗ |
| 2023-02-09 | Yoo David Jin | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-09 | Whang Jun Chul | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-09 | Roberts Rad | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-09 | REED STEVEN | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-09 | Park Jin Whan | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-09 | Hwang Kuk Hyoun | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,725,000 | — | ↗ |
| 2023-02-09 | Euh Hosun | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-09 | Chung In Chul | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-09 | Bellevue Global Life Science Investors LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,725,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-14.9K
Shares Outstanding
25.03M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Constance Hofer | Chief Scientific Officer | 2M | — |
| Kuk Hyoun Hwang | Chairman & Chief Executive Officer | 400.0K | male |
| Jun Chul Whang | Chief Legal Officer, Secretary & Director | 341.7K | male |
| Gihyoun Bang | Chief Financial Officer | 300.0K | male |
| Yeiseok Kim | Chief Operating Officer | — | male |
| Senyon Choe | Founder & CEO of Darnatein | — | male |
| Tim Smith | Corporate Secretary & Global IR | — | male |
| Chankyu Park | Chief Executive Officer of RMC | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OSRH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
